Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medivive vs Spry

Medivive
Graded #343

Higher grade

vs+2.6000000000000014
Spry
Graded #409

Lower grade

The verdict

Medivive takes it — 59.4/100 to 56.8/100.

Medivive grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medivive is a US telehealth service offering compounded semaglutide and tirzepatide for weight loss, filled through a licensed pharmacy, with providers licensed in all 50 states and no insurance required.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedivive +16
70
54
Dose & formulationSpry +24
40
64
Clinical oversightMedivive +8
63
55
Labs & monitoringMedivive +12
64
52
FulfillmentEven
61
61
Contract termsEven
55
55
Medivive · left barSpry · right bar

The numbers

MetricMediviveSpry
WeighScore59.4/10056.8/100
GradeCC
Scorecard rank#343#409
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Medivive

Graded #343 · C

Strengths

  • Compounded semaglutide and tirzepatide with providers licensed in all 50 states
  • No insurance required; one-stop for GLP-1 plus TRT, NAD+ and longevity care
  • Medication filled through a licensed pharmacy

Where it loses points

  • Monthly pricing not published; disclosed only after an AI intake
  • No legal entity or named pharmacy disclosed
  • Service states are not individually listed
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard